Skip to main content

Open Access Development of a simple LC-MS/MS method for determination of rebamipide in human plasma and its application to a bioequivalence study

Download Article:
 Download
(PDF 2,997.7 kb)
 

Abstract:

The purpose of this study was to design a simple and rapid liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for a rebamipide bioequivalence study in healthy Chinese male volunteers. In this method, sample pretreatment involved simple protein precipitation with venlafaxine as the internal standard. Analysis was achieved on a ZORBAX SB-C18 column with a concentration range of 6∼1200 ng/mL. Rebamipide tablets from Yuanlijian (test, Hangzhou, China) and from Otsuka (reference, Hangzhou, China) were evaluated following a single 300 mg oral dose to 20 healthy volunteers. Bioequivalence was determined by calculating 90 % confidence intervals (90 % CI) for the ratio of C max, AUC 0–t and AUC 0–∞ values for the test and reference products, using logarithmic transformed data. The 90 % confidence intervals for the ratio of C max (83.7∼118.4 %), AUC 0–t (91.1∼113.4 %) and AUC 0–∞ (90.6∼113.2 %) values for the test and reference products were within the interval (80.0∼125.0 % for AUC, and 70∼143 % for C max), proposed by State of Food and Drug Administration [SFDA, 2005. China]. It was concluded that the two rebamipide tablets were bioequivalent in their rate and extent of absorption and the method met the principle of quick and easy clinical analysis.

Document Type: Research Article

DOI: http://dx.doi.org/10.1691/ph.2012.2018

Publication date: November 1, 2012

More about this publication?
  • Pharmazie is one of the world's leading pharmaceutical journals. As a peer-reviewed scientific journal, DiePharmazie is regularly indexed in Current Contents/Life Sciences, Excerpta Medica, Analytical Abstracts, International Pharmaceutical Abstracts, Beilstein Current Facts in Chemistry, Chemical Engineering and Biotechnology Abstracts (CEABA) and Science Citation Index.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Terms & Conditions
  • ingentaconnect is not responsible for the content or availability of external websites
govi/pharmaz/2012/00000067/00000011/art00004
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more